Abstract

Objective: In the DURATION-1 study, the safety and efficacy of 30 weeks of treatment with the GLP-1 receptor agonist exenatide once weekly (exenatide QW; 2mg) was compared to exenatide BID in 295 patients with type 2 diabetes. We now report the safety and efficacy of exenatide QW in a) patients who continued treatment for an additional 22 weeks (52 weeks total), and b) patients who switched from exenatide BID to exenatide QW after 30 weeks.

Research Design and Methods: In this randomized, multicenter, comparator-controlled, open-label trial, 258 patients entered the 22-week open-ended assessment phase (n=128 QW-only; n=130 BID→QW). A1C, fasting plasma glucose (FPG), body weight, blood pressure, fasting lipids, safety, and tolerability were assessed.

Results: Patients continuing exenatide QW maintained A1C improvements through 52 weeks (−2.0% [−2.1 to −1.8%]; LS mean [95% CI]). Patients switching from exenatide BID to exenatide QW achieved further A1C improvements; both groups exhibited the same A1C reduction and mean A1C (6.6%) at week 52. At week 52, 71% and 54% of all patients achieved an A1C <7.0% and ≤6.5%, respectively. In both treatment arms, FPG was reduced by >40 mg/dL and body weight was reduced by >4 kg after 52 weeks. Nausea occurred less frequently in this assessment period and was predominantly mild. No major hypoglycemia was observed.

Conclusion: Exenatide QW elicited sustained improvements in glycemic control and body weight through 52 weeks of treatment; patients switching to exenatide QW experienced further improvements in A1C and FPG, with sustained weight loss.

ClinicalTrials.gov identifier: NCT00308139